Hartmut Rehwinkel

USPTO Granted Patents = 53 (Patent Applications = 10)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 18 (Patent Applications = 19)

Average Co-Inventor Count = 7.2

ph-index = 8

Forward Citations = 209(Granted Patents)

Forward Citations (Not Self Cited) = 154(Oct 12, 2025)

Inventors with similar research interests:

Company Filing History:

21 out of 1,384

Schering Aktiengesellschaft

patents

15 out of 378

Bayer Pharma Aktiengesellschaft

patents

10 out of 192

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

patents

6. 1 out of 1

Bayer Pharma Aktiengesselschaft

patent

7. 1 out of 1

Schering Aktiengsellschaft

patent

where one patent can have more than one assignee

Years Active: 1992-2021

Loading Chart...

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10919862 - Fused imidazoles as mIDH1 inhibitors (2021-02-16),

2. 10442772 - Benzimidazol-2-amines as mIDH1 inhibitors (2019-10-15),

3. 10138226 - Benzimidazol-2-amines as MIDH1 inhibitors (2018-11-27),

4. 10137110 - 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors (2018-11-27),

5. RE47047 - 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents (2018-09-17),

6. 9957235 - Benzimidazol-2-amines as mIDH1 inhibitors (2018-05-01),

7. 9951027 - Benzimidazol-2-amines as MIDH1 inhibitors (2018-04-24),

8. 9738632 - Phenyl and benzodioxinyl substituted indazoles derivatives (2017-08-22),

9. 9604989 - Imidazopyridazines as Akt kinase inhibitors (2017-03-28),

10. 9512110 - Phenyl and benzodioxinyl substituted indazoles derivatives (2016-12-06),

11. 9370517 - Substituted pyrazolopyrimidines as Akt kinase inhibitors (2016-06-21),

12. 9260435 - Substituted imidazopyrazines as Akt kinase inhibitors (2016-02-16),

13. 9206185 - Imidazopyridazines as Akt kinase inhibitors (2015-12-08),

14. 8987286 - Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway (2015-03-24),

15. 8987273 - Substituted imidazo[1,2-B]pyridazines (2015-03-24),

Certainly! Here is the article about inventor Hartmut Rehwinkel:

Title: Unveiling the Innovative Mind of Hartmut Rehwinkel

Introduction:

Hartmut Rehwinkel, a distinguished inventor hailing from Berlin, Germany, has left a significant mark in the domain of pharmaceutical innovations with his prolific work and numerous patents.

Latest Patents:

Rehwinkel's latest patents showcase his groundbreaking research in the field of oncology. His inventions, namely "Fused imidazoles as mIDH1 inhibitors" and "Benzimidazol-2-amines as mIDH1 inhibitors," present novel compounds and methods for the treatment of neoplasms, emphasizing his commitment to advancing medical science.

Career Highlights:

Throughout his career, Rehwinkel has amassed an impressive portfolio of 53 patents, demonstrating his expertise and dedication to driving innovation in the pharmaceutical industry. He has made significant contributions while working at renowned companies such as Schering Aktiengesellschaft and Bayer Pharma Aktiengesellschaft.

Collaborations:

In his journey of innovation, Rehwinkel has collaborated with esteemed colleagues such as Markus Berger and Stefan Jaroch, fostering a culture of teamwork and knowledge sharing to push the boundaries of scientific discovery.

Conclusion:

In conclusion, Hartmut Rehwinkel stands as a shining example of an inventive mind shaping the landscape of pharmaceutical advancements. His relentless pursuit of excellence and passion for innovation continue to inspire and pave the way for future breakthroughs in the realm of medical research.

If you have any more specific requests or need further information, feel free to ask!

This text is generated by artificial intelligence and may not be accurate.